November 1st, 2019

Podcast 240: Overuse of statins for primary prevention of cardiovascular events

(6 votes, average: 3.67 out of 5)

Running time: 23 minutes

Paula Byrne set out to understand what the available data tell us about how many people are taking statins for primary prevention — and how much good is it likely doing them?

Also, how do you discuss their possible harms and benefits with patients?

Links:

Paula Byrne and colleagues’ analysis in The BMJ

Kausik Ray meta analysis in JAMA Internal¬† Medicine

Kausik Ray 2010 Clinical Conversations interview

NEJM Journal Watch General Medicine comparison of statin guidelines

One Response to “Podcast 240: Overuse of statins for primary prevention of cardiovascular events”

  1. Richard M. Fleming, PhD, MD, JD says:

    The use of statins, PCSK9-inbhibitors and other treatments, focusing on reducing blood cholesterol levels, ignores the research we have published demonstrating that changes in blood tests for cholesterol, Lp(a), fibrinogen, homocysteine, C-RP, and the other factors laid out in my “Inflammation and Heart Disease Theory” published in 1999, do NOT correlate with changes in CAD itself. Qualitative Imaging or the use of serum blood tests do NOT aid in the decision making process. True Quantitative measurement is needed – FMTVDM – if we are to objectively find the answers to who, when and how, primary prevention patients should be treated with these medications.

Leave a Reply

Your email address will not be published. Required fields are marked *

Note: This is a moderated forum. By clicking on the "Submit Comment" button below, you agree to abide by the NEJM Journal Watch Terms of Use.

Our physician bloggers cannot respond to requests for personal medical advice, and recommend patients discuss health issues with their individual physicians.

Clinical Conversations

About the Podcast

To subscribe:

Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.